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Keypoints:  
A PCV-10 booster was generally less immunogenic than a PCV-13 booster in PCV-13 primed 
children. It may be more appropriate to give a PCV-13 booster to PCV-13 primed children although 
the clinical significance of these findings remains unclear.  
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Abstract 
Background  Both the 13- and 10-valent pneumococcal conjugate vaccines (PCV-13 and PCV-10) 
are immunogenic and effective against vaccine-type pneumococcal disease when given to young 
children. However, limited data are available regarding the interchangeability of these two vaccines.  
Methods  UK children (n=178) who had previously been vaccinated with PCV-13 at 2 and 4 months 
were randomized 1:1 to receive a booster of either PCV-13 or PCV-10 at 12 months of age. PCV-13 
vaccine-type anti-polysaccharide serum IgG concentrations and opsonophagocytic assay (OPA) titers 
were measured before and at 1 and 12 months following vaccination. The primary objective was to 
assess non-inferiority of PCV-10 compared to PCV-13. 
Results  For 8 out of the PCV-10 serotypes at least 97% of participants in both groups had IgG 
concentrations ≥0.35 µg/ml at 1 month after vaccination; inferior responses were seen for serotypes 5 
and 9V following a booster dose of PCV-10 compared with PCV-13. Post-booster geometric mean 
IgG concentrations and OPA titers were significantly superior for most serotypes in PCV-13 compared 
with PCV-10 recipients whereas similar or inferior responses were seen for serotypes 4, 18C and 19F. 
Conclusions  In PCV-13 primed infants, a booster dose of PCV-10 is generally less immunogenic 
than a PCV-13 booster. For the 3 serotypes in PCV-10 with higher antigen content and/or conjugation 
to a diphtheria or tetanus toxoid carrier protein, higher or similar booster responses were seen in PCV-
10 and PCV13 recipients. Although these findings suggest that responses are generally better with a 
PCV13 booster among PCV-13 primed children, the clinical significance of these differences in 
immunogenicity remains unclear. 
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Introduction 
The encapsulated bacterium Streptococcus pneumoniae commonly causes respiratory infections and 
may also cause severe infections such as meningitis and sepsis. Pneumococcal protein-polysaccharide 
conjugate vaccines (PCVs) were first routinely used in childhood immunization programs in children 
in the USA in 2000 and introduced as a 7-valent vaccine (PCV-7) into the UK infant immunization 
schedule in 2006, successfully reducing the burden of invasive pneumococcal disease in both countries 
(IPD) [1-3]. Newer PCVs with extended serotype coverage became available in 2009 including either 
an additional 3 (PCV-10) or 6 (PCV-13) serotypes. Both vaccines are immunogenic and effective 
against IPD when given to young children in a series of 3-4 vaccine doses [3-6]. Although both PCV-
10 and PCV-13 share 10 serotypes, they differ substantially in the concentrations of polysaccharides, 
the method of conjugation, and the type and concentrations of the carrier proteins [7]. 
There are several potential advantages of interchanging PCVs and using PCV-10 in PCV-13 primed 
children. The use of a novel carrier protein such as nontypeable Haemophilus influenzae (NTHi)-
derived protein D in PCV-10, which is not closely related to an antigen included in any concurrently 
or previously administered routine vaccine minimizes the risk of interference related to the carrier 
protein although the effect is usually seen in primary vaccination [8]. This in turn may enhance 
immune responses against the contained pneumococcal serotypes. In PCV-10, most serotypes are 
conjugated to protein D, which has the potential to induce responses that may protect children against 
NTHi disease through an immune response generated by the carrier protein [9, 10]. Interchanging 
PCVs may help to improve our understanding of vaccine immunobiology, addressing unanswered 
questions in relation to the interaction of conjugate vaccines with the immune system [11] and the 
poor booster responses with certain serotypes [7]. 
This study aimed to investigate the potential of an alternative booster vaccine to be given to 12-month 
old children who have been primed with PCV-13 in infancy. IgG concentrations and OPA titers for 
PCV-13 serotypes were assessed before, 1 and 12 months following the booster. The safety and 
reactogenicity of the 12-month booster was assessed using diary cards containing parental reports of 
local and systemic reactions following vaccination.  
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Methods 
Participants, recruitment and design  
The study was a randomized controlled clinical trial, which was open-labeled for participants and 
clinical trial staff, but blinded for laboratory staff. Ethical approval was obtained from the Oxfordshire 
Research Ethics Committee (reference number 11/SC/0473) and the study was registered on 
Clinicaltrials.gov (registration number NCT01443416). Participants were recruited primarily by 
information booklets mailed out via the UK National Health Application and Infrastructure Services 
who are responsible for the central NHS patient database. Potential study participants were healthy 12 
month (range 50-58 week) old children at the time of enrolment, who were available for the entire 
study period and had received all primary vaccines according to the UK routine immunization 
schedule including 2 immunizations of PCV-13 at less than 6 months of age with a gap of at least 6 
weeks between the two vaccinations. Absolute and temporary exclusion criteria are summarized in 
Table S1. Following written informed consent, study participants were randomly allocated to receive a 
booster dose at 12 months of either PCV-13 (Prevenar 13®, Pfizer) or PCV-10 (Synflorix, GSK 
Biologicals). 
Vaccines and interventions 
Most serotypes contained in PCV-10 are conjugated individually to protein D (total dose 9-16 µg), a 
recombinant form of a lipoprotein of non-typeable H. influenzae; serotypes 18C and 19F 
polysaccharides are conjugated to tetanus toxoid (5-10 µg) and diphtheria toxoid (3-6 µg), respectively 
(Table 1). PCV-13 contains saccharides from pneumococcal serotypes 3, 6A, and 19A in addition to 
PCV-10 serotypes, individually conjugated to cross-reacting material (CRMl97, total dose of around 34 
µg) (Table 1). Both vaccines (0.5 ml) were administered intramuscularly using a 0.6 x 25 mm 23 
gauge needle into the anterolateral aspect of either thigh. Combined Haemophilus influenzae type 
b/group C meningococcal vaccine and measles, mumps and rubella vaccine were given at 13 months 
but did not form part of the study evaluation. 
Laboratory measurements 
Serum was separated within 24 hours at the study site and stored at -20 °C. Antibody measurements 
were performed at the WHO pneumococcal reference laboratory at University College London. Serum 
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concentrations of total anticapsular immunoglobulin G (IgG) for PCV-13 serotypes were identified by 
ELISA method after absorption with C polysaccharide-containing cell wall extract and 22F 
polysaccharide, and expressed as µg/ml. Opsonophagocytic assay (OPA) titers against PCV-13 
serotypes were measured using a multiplex opsonophagocytic assay [12]. The lower limit of 
quantitation (LLOQ) for all serotypes as established during the validation was 0.150 µg/ml for IgG 
concentrations measured by ELISA and 8 for OPA titers. Values below the LLOQ were replaced with 
0.075 µg/ml and 4, respectively. 
Statistical analysis 
Data were log-transformed prior to analysis and group summaries presented as geometric means with 
associated two-sided, 95% confidence intervals (CI). In addition, the geometric mean fold-rise for the 
serotype-specific antibody measurements was derived from the exponent of the within-person 
difference between the log-transformed individual assay result before and after the booster dose. The 
proportion of study participants achieving thresholds of 0.35 µg/ml for IgG concentrations, or 8 for 
OPA titers were calculated within each group and confidence intervals computed using the binomial 
exact method. Similar analyses were performed to calculate proportions and 95% CI for rates of local 
and systemic reactions. Chi-squared test (or Fisher’s exact tests when expected counts were less than 
5) were used to compare proportions of participants between groups. Two-sample t-tests or analysis of 
covariance was used to compare the continuous variables with adjustment for baseline values where 
appropriate. Comparisons between the two groups were carried out based on treatment allocation. 
Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., USA) and R [13]. 
Study objectives  
The primary objective of this study was to assess whether PCV-10 is non-inferior to PCV-13 using 
proportions of participants with IgG concentrations ≥0.35 µg/ml for PCV-10 serotypes PCV-10, one 
month following booster vaccination at 12 months of age with PCV-10 or PCV-13. Non-inferiority of 
PCV-10 would be shown if the confidence interval for the difference between groups (PCV-10 – 
PCV-13) did not include values less than -10% (non-inferiority margin). The sample size of 84 
participants in each of the vaccine groups was calculated to allow assessment of non-inferiority with a 
margin of 10% using 80% power and 2.5% significance level allowing for a 15% drop-out rate. 
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During the course of the study, blood samples for less than 85% of participants were available at 13 
months of age, therefore more study participants were recruited following amendment of the protocol. 
The Intention to treat (ITT) population for immunogenicity consisted of all participants receiving a 
dose of PCV-10 or PCV-13 and providing a blood sample at age 13 months. Participants with pre-
defined deviations from protocol were removed from the per-protocol (PP) population. The PP 
population was used for primary non-inferiority analysis, with a sensitivity analysis performed on the 
ITT population. All other analyses were conducted on an ITT population; secondary objectives 
reported here included the immunogenicity and reactogenicity of the booster. Other secondary 
objectives that will be reported separately were the assessment of immediate pain at time of injection 
of the PCV booster and the investigation of antigen-specific peripheral blood memory B cells in 
response to vaccination. 
Results 
178 children aged 11-13 months, from the Oxfordshire region, were recruited and randomized in a 1:1 
ratio into 2 groups to receive one dose of either PCV-10 or PCV-13 at 12 months of age. Figure 1 
shows the number of participants and their flow through the study. Baseline demographics of 
randomized participants are shown in Table 2.  
One child was enrolled at age 11 months and 5 days, below the minimum age for inclusion, and was 
therefore excluded from the PP population (Figure 1), but included in the ITT population. There were 
a number of protocol deviations related to the timing of visits, none of which were thought to 
significantly affect any of the outcome measures. Hence, none of these study participants were 
excluded from the PP population. There were 5 serious adverse events (febrile illness, suspected 
meningococcal sepsis, viral gastroenteritis, viral wheeze, febrile convulsion) reported during the study 
none of which were considered related to study vaccines and all participants recovered.  
At baseline, there were significantly higher IgG GMC seen in the PCV-10 compared with the PCV-13 
group for serotypes 19F and 19A (Figure 2). For serotype-specific geometric mean OPA titers (GMT), 
group differences were found only for serotype 3 with a significantly higher OPA GMT in PCV-10 
compared with PCV-13 recipients (Figure 3).  
Non-inferiority assessment of PCV-10 as an alternative 12-month booster (PP population) 
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Table 3 shows the results of the primary endpoint analysis. IgG responses to serotypes 5 and 9V in the 
PCV-10 group were inferior to the PCV-13 group at 13 months when proportions of participants with 
serotype-specific IgG concentrations ≥0.35 µg/ml were compared between groups.  
Short-term antibody response to a booster dose of PCV-10 compared with PCV-13 (ITT population) 
One month following the booster vaccine, at least 97% of participants in each group had IgG 
concentrations ≥0.35 µg/ml for the serotypes they were vaccinated against with the exception of 
serotypes 5 and 9V in the PCV-10 group. For these 2 serotypes, which are common to both PCV-10 
and PCV-13, the proportions of participants with serotype-specific IgG above the threshold were 
significantly higher in PCV-13 compared with PCV-10 recipients (Figure S1 & Table S2). In addition, 
these proportions were also higher in the PCV-13 group for 2 out of the 3 serotypes only included in 
PCV-13, namely serotypes 3 and 6A but not serotype 19A (Figure S1 & Table S2). 
Post-booster IgG GMC were significantly higher in the PCV-13 compared with the PCV-10 group for 
the majority of serotypes common to both vaccines (1, 5, 6B, 7F, 9V, 14, and 23F) as well as for the 
serotypes only included in PCV-13 (3, 6A, and 19A) whereas GMCs were significantly higher in 
PCV-10 compared with PCV-13 recipients only for serotypes 4, 18C and 19F (Figure 2 & Table S4).  
An analysis of covariance model that adjusted for baseline values, age, sex and ethnicity was used to 
investigate changes from baseline in IgG concentrations between groups. Significant increases in IgG 
concentrations were observed in both groups for all serotypes between 12 and 13 months of age and 
group differences from adjusted and unadjusted analyses were similar to differences observed in 
analysis of 13-month values alone (Table S6). 
Serotype-specific functional antibodies were assessed by OPA for all PCV-13 serotypes. One month 
following the booster, at least 98% of participants had titers ≥8 and there were no observable group 
differences, for all PCV-10 serotypes except for serotypes 1, 5 and 9V; for these serotypes the 
proportion of participants with OPA titers ≥8 was higher in the PCV-13 than PCV-10 group. These 
proportions were also higher for all 3 serotypes (3, 6A, and 19A) only contained in PCV-13 (Table S7 
& Figure S2).  
Significantly higher post-booster GMT were seen in the PCV-13 than the PCV-10 group for most 
serotypes common to both vaccines as well as for all 3 serotypes only included in PCV-13. For 
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serotypes 4 and 18C there were no significant differences between the groups and for serotype 19F, 
the OPA response was significantly higher in the PCV-10 than the PCV-13 group (Figure 3 & Table 
S9). 
For both study groups significant increases in OPA titers for all serotypes with the exception of 
serotype 3 in the PCV-10 group were seen between 12 and 13 months of age (Table S11). Analyses of 
change from baseline to 13 months in OPA titers with adjustment for baseline values, age, sex and 
ethnicity, gave similar results to unadjusted analyses of 13 month values although group differences in 
immunogenicity for serotypes 1 and 19F were no longer observed (Table S11).  
One-year antibody persistence following a booster dose of PCV-10 compared with PCV-13 (ITT 
population) 
Group differences in proportions above the IgG or OPA thresholds were observed for a number of 
serotypes at 24 months of age, i.e. 12 months following the booster. These proportions were similarly 
greater for both measurements for PCV-13 compared with PCV-10 recipients for serotypes 6B, 7F and 
6A and lower for serotype 19F (Figures S1 and S2).  
When persistence of IgG concentrations and OPA titers were assessed at 24 months of age, significant  
differences remained between the groups. IgG GMCs and OPA GMTs were greater in PCV-13 
compared with PCV-10 recipients for serotypes 6B, 7F, 9V, and 6A whereas both measurements were 
significantly higher in the PCV-10 compared with the PCV-13 group for serotype 19F (Figures 2 & 3; 
Tables S5 & S10).  
When analyses of change from baseline to 24 months adjusted for baseline antibody, age, sex and 
ethnicity, group differences were similar to unadjusted analyses (Tables S12 & S13) with a significant 
decline in serotype-specific IgG antibodies and OPA titers from 13 to 24 months for all serotypes 
except for OPA titers against serotype 3 in the PCV-10 group (not shown). 
Reactogenicity 
The reactogenicity profile of the booster vaccination was similar regardless of whether participants 
had received PCV-10 or PCV-13 (Table S14). Local reactions such as redness, hardness, and swelling 
were either absent or mild in most cases. Moderate or severe localized pain was reported by almost 
13% of parents of study participants across both groups; irritability, drowsiness and decreased appetite 
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were recorded in 53%, 29% and 29% of participants of both groups combined, respectively (Table 
S15). Low-grade fever (38-39°C) was noted in 4% of participants and 4 children (2%) had a 
temperature of >39°C in the first 4 days following booster vaccination (Table S15). The majority of 
these reported adverse effects of vaccination were short-lived lasting 1-3 days (Table S16). 
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Discussion 
This is the first study to investigate the interchangeability of PCV-10 and PCV-13 as a 12-month 
booster in children primed with PCV-13. A robust antibody response was induced by both vaccines at 
one year of age when administered to PCV-13 primed children. For the primary objective, PCV-10 
was non-inferior to PCV-13 for 8 of the PCV-10 serotypes. However, there were 22% and 10% less 
fewer study participantstoddlers with IgG concentrations ≥0.35 µg/ml against serotypes 5 and 9V, 
respectively, in the PCV-10 than the PCV-13 group (Table 3), possibly representing a clinically 
relevant difference.  
When post-booster serotype-specific IgG GMC and OPA GMT were considered, PCV-13 was more 
immunogenic for the majority of serotypes common to both vaccines. There are no published large 
head-to-head clinical trials comparing PCV-10 and PCV-13. In a recent small study in which children 
were vaccinated with either PCV-10 or PCV-13 at 2, 3, 4 and 11 months of age, serotype-specific IgG, 
plasma and memory B cells against serotypes 1, 6B, 7F, and 19F were investigated and compared 
between the groups before and 7-9 days following the booster dose [14]. This study showed 
statistically superior post-booster IgG responses in the PCV-13 group to one (19F) out of the 4 
serotypes common to both vaccines. These findings are in contrast to our study in which responses to 
serotype 19F were lower in PCV-13 recipients using both IgG levels and OPA titers as read-out at 1 
and 12 months following the booster. In the aforementioned study by van Westen et al., post-booster 
responses were measured in a considerably smaller group of children at 7-9 days rather than 1 month 
following vaccination, which may explain this difference. 
In our study, only responses against serotypes 4, 18C, and 19F were consistently similar or statistically 
superior (19F) at 13 months in the PCV-10 compared with the PCV-13 group. Interestingly, these 3 
serotypes are contained in PCV-10 in a higher concentration than the other serotypes (3 µg vs. 1 µg) 
and also compared with the same serotypes in PCV-13 (3 µg vs. 2.2 µg). In addition, PCV-10 
serotypes 18C and 19F are conjugated to a non-protein D carrier protein – tetanus and diphtheria 
toxoid, respectively – and both these antigens are included in previously administered routine 
childhood vaccines. This may also partly explain the better antibody response to these two serotypes 
compared with other serotypes in PCV-10 recipients as priming would have already happened through 
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these other vaccines. Although there are no immunogenicity studies directly comparing PCV-10 with 
PCV-13, antibody responses to PCV-10 have previously been compared with those elicited by PCV-7 
[15]. Vesikari et al. showed that post-booster antibody responses in participants who had exclusively 
received either vaccine were superior in the PCV-7 group for the majority of PCV-7 serotypes with the 
exception of serotypes 18C (similar) and 19F (inferior) indicating that PCV-7 is generally more 
immunogenic than PCV-10. In the same study, antibody responses were largely similar between the 
group of children who had exclusively received PCV-7 and those who had been primed with PCV-7 
followed by a booster dose of PCV-10 [15]. These findings suggest that similar antibody responses 
can be achieved when switching from one PCV to another containing similar capsular serotypes 
despite a difference in carrier proteins. However, Vesikari et al. also demonstrated that there were 
markedly lower antibody responses to serotypes 1, 5, and 7F (not included in PCV-7) in children in 
the PCV-7/PCV-10 compared with the PCV-10/PCV-10 group [15] indicating that serotype-specific 
priming even when performed with a different vaccine and carrier protein is essential for obtaining 
sufficiently high booster responses. In a case-control study performed in Canada the effectiveness 
against all IPD caused by PCV-13 serotypes of a mixed PCV schedule consisting of 2 doses of PCV-
10 followed by one dose of PCV-13 was similar to alternative schedules in which children were only 
vaccinated with PCV-10 or PCV-13 [4]. These findings suggest that interchanging PCVs does not per 
se result in inferior protection compared with schedules using a single type of PCV although the 
combination of priming with PCV-13 and boosting with PCV-10 was not assessed in this study.  
For the three serotypes that are exclusive to PCV-13 (3, 6A and 19A), not only PCV-13 but also PCV-
10 recipients showed an increased antibody response following booster vaccination, which may 
represent generation of cross-reactive antibodies through vaccination with the related serotypes 6B and 
19F. Not surprisingly, the antibody responses against these 3 serotypes were greatly lower in the PCV-
10 compared with the PCV-13 group (Figures 2 and 3).  
In the present study, antibody persistence up to 1 year following the booster was assessed using both 
serotype-specific IgG antibody concentrations and OPA titers against PCV-13 serotypes. Over the 12-
month period following the booster, there was a rapid decline in antibody in both groups. IgG levels 
and OPA titers at 24 months were largely determined by the amount of antibody detected 1 month 
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post-booster at 13 months of age, which has been previously demonstrated where the same PCV was 
used for both priming and boosting [16]. These findings suggest that boosting with a different vaccine 
containing the same capsular serotypes, albeit conjugated to different carrier proteins, induces an 
immune response that is not only driven by short-lived extrafollicular B cells but also the generation of 
long-lived plasma cells, a hallmark of immune memory.  
Conclusions 
Our study showed that a booster dose of PCV-10 at 12-month of age is generally less immunogenic 
than a PCV-13 booster in PCV-13 primed children. Post-booster antibody responses that were similar 
or superior in the PCV-10 group were seen for serotypes 4, 18C and 19F, which are contained in PCV-
10 with higher antigen content and/or conjugation to a diphtheria or tetanus toxoid carrier protein. The 
clinical significance of the observed differences in immunogenicity remains unknown although our 
findings suggest that it may be more appropriate to give a PCV-13 booster to PCV-13 primed children. 
Further studies in children primed with PCV-10 and then boosted with PCV-13 are needed to expand 
our understanding and the clinical implications of interchangeable PCV schedules.  
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Table 1  Pneumococcal polysaccharide concentrations and serotype-specific carrier proteins 
contained in PCV-10 and PCV-13. 
 PCV-10* PCV-13** 
Serotype Dose of  
polysaccharide (g) 
Carrier protein Dose of  
polysaccharide (g) 
Carrier protein 
1 1 Protein D 2.2 CRM197 
4 3 Protein D 2.2 CRM197 
5 1 Protein D 2.2 CRM197 
6B 1 Protein D 4.4 CRM197 
7F 1 Protein D 2.2 CRM197 
9V 1 Protein D 2.2 CRM197 
14 1 Protein D 2.2 CRM197 
18C 3 Tetanus toxoid 2.2 CRM197 
19F 3 Diphtheria toxoid 2.2 CRM197 
23F 1 Protein D 2.2 CRM197 
3   2.2 CRM197 
6A   2.2 CRM197 
19A   2.2 CRM197 
*contains 0.5 mg aluminium phosphate 
**contains 5mM succinate buffer and 0.125 mg aluminum phosphate 
 
Table 2  Baseline demographics by group. 
 
PCV-10 (n = 87) PCV-13 (n = 90) 
N (%) N (%) 
Age (Months)     
 Mean (SD) [Min-Max] 12.6 (0.4) [11.1-13.3] 12.7 (0.4) [11.7-13.5] 
Sex     
 Male 46 (52.9) 58 (64.4) 
 Female 41 (47.1) 32 (35.6) 
Ethnicity     
 White Caucasian/ European 78 (89.7) 74 (82.2) 
 Other 9 (10.3) 15 (16.7) 
 Unknown 0 0 1 (1.1) 
 
Table 3  Proportion of participants with IgG antibody concentrations ≥0.35 µg/ml by serotype 
and vaccine group at 13 months and difference between groups (PP population). 
 PCV-10 (n = 69) PCV-13 (n = 74) PCV-10 – PCV-13 
Serotype N 
Proportion IgG  
≥0.35 µg/ml (95% CI) N 
Proportion IgG  
≥0.35 µg/ml (95% CI) Difference (95% CI) 
1 69 0.986 (0.922, 1.000) 74 0.987 (0.927, 1.000) -0.001 (-0.040, 0.038) 
4 69 1.000 (0.948, 1.000) 74 0.987 (0.927, 1.000) 0.014 (-0.013, 0.040) 
5 69 0.739 (0.619, 0.837) 74 0.960 (0.886, 0.992) -0.220 (-0.336, -0.105) 
6B 69 0.971 (0.899, 0.997) 73 1.000 (0.951, 1.000) -0.029 (-0.070, 0.012) 
7F 69 0.986 (0.922, 1.000) 74 1.000 (0.951, 1.000) -0.015 (-0.043, 0.014) 
9V 69 0.884 (0.784, 0.949) 74 0.987 (0.927, 1.000) -0.102 (-0.184, -0.021) 
14 69 1.000 (0.948, 1.000) 74 1.000 (0.951, 1.000) 0.000 (0.000, 0.000) 
18C 69 1.000 (0.948, 1.000) 74 0.973 (0.906, 0.997) 0.027 (-0.011, 0.065) 
19F 69 1.000 (0.948, 1.000) 74 0.987 (0.927, 1.000) 0.014 (-0.013, 0.040) 
23F 63 1.000 (0.943, 1.000) 74 1.000 (0.951, 1.000) 0.000 (0.000, 0.000) 
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Figure legends  
Figure 1  CONSORT diagram showing the flow through the study. One study participant receiving 
PCV-10 was excluded from the analysis of the primary objective because of major protocol 
violation resulting in n = 69 in the PCV-10 group at the 13-mo visit. 
 
Figure 2 Serotype-specific IgG geometric mean concentrations by serotype and vaccine group at 
all 3 study time points. Groups were compared using independent samples t-tests using 
log10-transformed data with Satterthwaite’s correction for unequal variances and stars 
indicate the associated p-value (*** <.001; ** <.01; * <.05). 
 
Figure 3 Serotype-specific geometric mean OPA titers by serotype and vaccine group at all 3 study 
time points. Groups were compared using independent samples t-tests using log10-
transformed data with Satterthwaite’s correction for unequal variances and stars indicate 
the associated p-value (*** <.001; ** <.01; * <.05). 
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